Among patients with metabolic dysfunction-associated steatotic liver disease, the rate of advanced fibrosis is more than twice as high in slim patients than in patients with overweight or obesity.
The ultrasound prevalence of NAFLD was 23% among a cohort of patients with IBD, with study results further identifying several clinical characteristics associated with IBD-NAFLD including age, gender, BMI, and waist circumference.
Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.
A single daily low dose of aspirin significantly reduced hepatic fat fraction and liver transaminase levels in a randomized trial in patients with metabolic-associated steatotic liver disease.
Omega-3 fatty acids downregulate expression of betacellulin in patients with NASH, providing a potential new avenue for prevention and treatment, a study has found.